CAJ | 학술논문

目的：分析探讨阿德福韦酯治疗慢性乙型肝炎的临床疗效。方法将2009年11月至2013年1月期间在我院治疗的105例慢性乙型肝炎患者随机分为两组，观察组58例口服阿德福韦酯片治疗，对照组47例用常规护肝降酶药治疗。48周后比较两组患者HBV-DNA转阴率、HBeAg/HBeAb血清转换率、ALT复常率以及肝纤维化指标变化情况。结果观察组HBV-DNA转阴率、HBeAg/HBeAb血清转换率及ALT复常率均高于对照组（P<0.05）；观察组患者治疗后的肝纤维化指标下降程度优于对照组（P<0.05）。结论阿德福韦酯在抗乙型肝炎病毒的同时延缓了慢性乙型肝炎患者肝纤维化的发生，对慢性乙型肝炎患者远期预后有着积极的影响意义。
목적：분석탐토아덕복위지치료만성을형간염적림상료효。방법장2009년11월지2013년1월기간재아원치료적105례만성을형간염환자수궤분위량조，관찰조58례구복아덕복위지편치료，대조조47례용상규호간강매약치료。48주후비교량조환자HBV-DNA전음솔、HBeAg/HBeAb혈청전환솔、ALT복상솔이급간섬유화지표변화정황。결과관찰조HBV-DNA전음솔、HBeAg/HBeAb혈청전환솔급ALT복상솔균고우대조조（P<0.05）；관찰조환자치료후적간섬유화지표하강정도우우대조조（P<0.05）。결론아덕복위지재항을형간염병독적동시연완료만성을형간염환자간섬유화적발생，대만성을형간염환자원기예후유착적겁적영향의의。
Objective To evaluate the clinical efficacy of adefovir in the treatment of chronic hepatitis B. Methods 105 cases of chronic hepatitis B patients in our hospital from November 2009 to January 2013 period were randomly divided into two groups, the observation group of 58 cases was taken with oral adefovir dipivoxil tablets treatment and the control group was taken with conventional liver reduced enzyme medication. The HBV-DNA negative rate, HBeAg/HBeAb seroconversion, ALT normalization rates, and changes in liver fibrosis after 48 weeks for the two groups were compared. Results The HBV-DNA negative rate, HBeAg/HBeAb seroconversion and ALT normalization ratesin the observation group were higher than the control group (P<0.05). After treatment, the degree of decreasing liver fibrosis in the observation group was better than the control group (P<0.05). Conclusion Adefovir dipivoxil in the time of anti-hepatitis B virus in chronic hepatitis B patients delay the occurrence of liver fibrosis, and it has long-term prognosis positive significance on significance for chronic hepatitis B patients.